Literature DB >> 9578508

Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men.

C Karlsson1, K Stenlöf, G Johannsson, P Mårin, P Björntorp, B A Bengtsson, B Carlsson, L M Carlsson, L Sjöström.   

Abstract

The present study has examined the short- and long-term effects of growth hormone (GH) treatment on the leptin system and energy expenditure. Thirty male individuals with abdominal obesity were randomised to GH or placebo treatment in a 9-month, double-blind study. The dose of GH was 9.5 microg/kg, administered subcutaneously every evening. Serum leptin concentrations were measured by a human leptin RIA. Total RNA was isolated from adipose tissue biopsies and leptin mRNA levels were determined by a semi-quantitative reverse transcriptase-PCR assay. Body composition was determined by potassium-40 and the basal metabolic rate (BMR) was measured by a computerised, ventilated, open-hood system. As compared with placebo, an overall decrease in serum leptin concentrations as assessed by the area under the curve (AUC) (P < 0.05) and an increase in BMR (AUC, P < 0.05) were observed during GH treatment. The overall GH-induced changes were due to marked changes in serum leptin concentrations and BMR after 6 weeks of treatment. After 9 months of GH treatment there was a significant reduction in body fat (BF) while serum leptin concentrations and BMR did not differ from baseline values. Leptin mRNA levels did not change over the study period. We speculate that long-term GH treatment induces a new energy balance steady state with decreased BF stores. The effects of GH on the leptin system is suggested to be of importance for the maintenance of a lower BF mass.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578508     DOI: 10.1530/eje.0.1380408

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].

Authors:  David C W Lau; James D Douketis; Katherine M Morrison; Irene M Hramiak; Arya M Sharma; Ehud Ur
Journal:  CMAJ       Date:  2007-04-10       Impact factor: 8.262

3.  Relationship between serum IGF-1 and skeletal muscle IGF-1 mRNA expression to phosphocreatine recovery after exercise in obese men with reduced GH.

Authors:  Sulaiman R Hamarneh; Caitlin A Murphy; Cynthia W Shih; Walter Frontera; Martin Torriani; Javier E Irazoqui; Hideo Makimura
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

4.  Leptin levels in relation to marital status and neuroendocrine function in Iraqi females with polycystic ovary syndrome.

Authors:  Ban H Khalaf
Journal:  Saudi Pharm J       Date:  2009-12-23       Impact factor: 4.330

Review 5.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.

Authors:  Darlene E Berryman; Camilla A M Glad; Edward O List; Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2013-04-09       Impact factor: 43.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.